We are live on ! Find out more
SOCM

SR One Capital Management Portfolio holdings

AUM $915M
1-Year Est. Return 209.71%
This Fund
S&P 500
This Quarter Est. Return
-3.33%
1 Year Est. Return
+209.71%
3 Year Est. Return
+484.66%
5 Year Est. Return
10 Year Est. Return
AUM
$195M
AUM Growth
-$36.8M
Cap. Flow
$0
Cap. Flow %
0%
Top 10 Hldgs %
100%
Holding
6
New
Increased
Reduced
Closed

Top Buys

No buys this quarter

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ACLX
1
DELISTED
Arcellx
ACLX
$142M 72.57%
3,946,630
MLYS icon
2
Mineralys Therapeutics
MLYS
$2.41B
$17.1M 8.75%
1,794,600
DSGN icon
3
Design Therapeutics
DSGN
$915M
$15.4M 7.89%
6,526,476
SPRY icon
4
ARS Pharmaceuticals
SPRY
$591M
$15.2M 7.77%
4,012,903
EFTR
5
DELISTED
eFFECTOR Therapeutics, Inc. Common Stock
EFTR
$4.03M 2.06%
272,885
NKTX icon
6
Nkarta
NKTX
$167M
$1.85M 0.95%
1,333,333

Similar funds

SR One Capital Management's Q3 2023 Portfolio in Review

As of Q3 2023, SR One Capital Management held 6 positions worth $195M, down 16% from $232M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Trading was light in Q3 2023: portfolio turnover was 0%. SR One Capital Management opened no new positions and made no exits, leaving the 6-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • SR One Capital Management's ten largest holdings make up 100% of its $195M portfolio in Q3 2023.
  • SR One Capital Management opened 0 new positions and closed 0 in Q3 2023.
  • SR One Capital Management's portfolio value fell 16% quarter-over-quarter to $195M.

Based on SR One Capital Management's 13F filing for Q3 2023, filed 13 Nov 2023.